See How We Can Help Eligible* Commercially Insured Patients with Amgen Prescription Costs

amgen first step

Your First Step: Register Your Office With the Program

The Amgen FIRST STEP program can help your eligible commercially insured patients meet their deductible, co-insurance, and co-payment for select Amgen products.

CALL to register your practice

Make a one-time call to the Register Terminal

  • Call 1-888-65STEP11-888-65STEP1
  • Submit your merchant ID for the credit card terminal your office will use to swipe Amgen FIRST STEP co-pay cards
ASSESSpatients for potential eligibility

Identify eligible patients taking an Amgen medication

Eligibility requirements and a list of brands covered by the Amgen FIRST STEP program are listed below. Other restrictions may apply

REGISTER Patient Registration

Assist patients with registration by having them fill out required forms, available at AmgenFIRSTSTEP.com:

  1. Enrollment form with eligibility questions Help your patient complete and submit
  2. Privacy Notice and Patient Authorization form Submit signed Privacy Notice and Patient Authorization form online or by fax (click on “Prefer to fax” button online and follow instructions)
  3. Register patient before any treatment. (See below for eligible Amgen products.) Upon approval, card will be activated
DELIVER information to your eligible patient

Review program details with your patient:

  • No out-of-pocket cost for the first dose or cycle
  • For subsequent doses, Amgen will pay the out-of-pocket amount in excess of $25 per dose (coverage limits vary by product)
  • No income eligibility requirement

Fax itemized Explanation of Benefits (EOB) within 45 days of initial swipe

To register or for more information, please visit AmgenFIRSTSTEP.com AmgenFIRSTSTEP.com or call 1-888-65STEP1 1-888-65STEP1 (1‑888‑657‑8371)(1‑888‑657‑8371). Monday to Friday 9am to 8pm ET. Closed on all major holidays


*Here's what your patient needs to qualify:

  • Must be prescribed BLINCYTO® (blinatumomab), Neulasta® (pegfilgrastim), Neulasta® Onpro™, NEUPOGEN® (filgrastim), Nplate® (romiplostim), XGEVA® (denosumab), Prolia® (denosumab), Vectibix® (panitumumab), IMLYGIC® (talimogene laherparepvec), or KYPROLIS® (carfilzomib)
  • Must have private commercial health insurance that covers medication costs for BLINCYTO® (blinatumomab), Neulasta® (pegfilgrastim), Neulasta® Onpro™, NEUPOGEN® (filgrastim), Nplate® (romiplostim), XGEVA® (denosumab), Prolia® (denosumab), Vectibix® (panitumumab), IMLYGIC® (talimogene laherparepvec), or KYPROLIS® (carfilzomib)
  • Must not be a participant in any federal-, state-, or government-funded healthcare program such as Medicare, Medicare Advantage, Medicare Part D, Medicaid, Medigap, Veterans Affairs (VA), the Department of Defense (DoD), or TRICARE®
  • May not seek reimbursement for value received from the Amgen FIRST STEP™ program from any third-party payers, including flexible spending accounts or healthcare savings accounts. If at any time patients begin receiving coverage under any federal-, state-, or government-funded healthcare program, patients will no longer be eligible to participate in the Amgen FIRST STEP™ Program and must call 1-888-65-STEP1 (1-888-657-8371) Monday through Friday, 9 am-8 pm ET, to stop participation. Restrictions may apply. Amgen reserves the right to revise or terminate this program, in whole or in part, without notice at any time. This is not health insurance. Program invalid where otherwise prohibited by law. 
  • Coverage Limits:

  • Program covers out-of-pocket medication costs for the Amgen product only. Program does not cover any other costs related to office visit or administration of Amgen product.
  • No out-of-pocket for first dose; $25 out-of-pocket cost for subsequent dose or cycle; for BLINCYTO® (blinatumomab), Neulasta® (pegfilgrastim), Neulasta® Onpro™, NEUPOGEN® (filgrastim), Nplate® (romiplostim), XGEVA® (denosumab), Vectibix® (panitumumab), and IMLYGIC® (talimogene laherparepvec) maximum benefit of $10,000 per patient per calendar year; for Prolia® maximum benefit of $3,000 per patient per calendar year; for KYPROLIS® (carfilzomib) maximum benefit of $20,000 per patient per calendar year. Patient is responsible for costs above these amounts.
  • Ongoing activation of the Amgen FIRST STEP™ card is contingent on the submission of the required Explanation of Benefits (EOB) form by the healthcare provider’s office within 45 days of use of the Amgen FIRST STEP™ card. Patients will be responsible for reimbursing the program for all amounts paid out if the EOB for the date of service is not received within 45 days.
  • Other restrictions apply. Not valid where prohibited by law. Amgen reserves the right to revise or terminate this program, in whole or in part, without notice at any time.
Additional resources Other helpful resources
  • Benefit Verification Center

    Helps you electronically manage your patients’ access to their treatments with benefit verification, claims processing,
    and secure messaging

    LOG IN OR REGISTER YOUR PRACTICE
  • We’re Here to Help

    Call 1-888-4ASSIST
    (1-888-427-7478)(1-888-427-7478)
    Monday to Friday
    9:00 am to 8:00 pm ET

    We’re Here to Help

    Call 1-888-4ASSIST
    (1-888-427-7478)(1-888-427-7478)
    Monday to Friday
    9:00 am to 8:00 pm ET

  • Amgen reimbursement specialist

    Whether by phone or in person, speak with someone who considers your case as important as you do

    CONNECT ME
  • LOCAL PAYER WIZARD

    State-specific payer policy information

    GET DETAILS NOW